[go: up one dir, main page]

FR2893841B1 - Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89) - Google Patents

Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89)

Info

Publication number
FR2893841B1
FR2893841B1 FR0511977A FR0511977A FR2893841B1 FR 2893841 B1 FR2893841 B1 FR 2893841B1 FR 0511977 A FR0511977 A FR 0511977A FR 0511977 A FR0511977 A FR 0511977A FR 2893841 B1 FR2893841 B1 FR 2893841B1
Authority
FR
France
Prior art keywords
isoquinolinesulfonamide
depigmenting
bromophenyl
propenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0511977A
Other languages
English (en)
Other versions
FR2893841A1 (fr
Inventor
Corine Bertolotto
Robert Ballotti
Flavie Luciani
Mehdi Khaled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires D'anjou Fr
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Galderma Research and Development SNC filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR0511977A priority Critical patent/FR2893841B1/fr
Priority to PCT/EP2006/068772 priority patent/WO2007060182A1/fr
Priority to ARP060105185A priority patent/AR057933A1/es
Publication of FR2893841A1 publication Critical patent/FR2893841A1/fr
Application granted granted Critical
Publication of FR2893841B1 publication Critical patent/FR2893841B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
FR0511977A 2005-11-25 2005-11-25 Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89) Expired - Lifetime FR2893841B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0511977A FR2893841B1 (fr) 2005-11-25 2005-11-25 Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89)
PCT/EP2006/068772 WO2007060182A1 (fr) 2005-11-25 2006-11-22 Utilisation de n-[2-[[3-(4-bromophenyl)-2-propenyl]amino] ethyl]-5- isoquinolinesulfonamide (h89) dans une composition pharmaceutique depigmentante
ARP060105185A AR057933A1 (es) 2005-11-25 2006-11-24 Composicion farmaceutica despigmentante que comprende n-(2-((3-(4- bromofenil)- 2- propenil ) amino) etil) -5- isoquinolinsulfonamida (h89)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0511977A FR2893841B1 (fr) 2005-11-25 2005-11-25 Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89)

Publications (2)

Publication Number Publication Date
FR2893841A1 FR2893841A1 (fr) 2007-06-01
FR2893841B1 true FR2893841B1 (fr) 2014-04-25

Family

ID=36934164

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0511977A Expired - Lifetime FR2893841B1 (fr) 2005-11-25 2005-11-25 Composition pharmaceutique depigmentante comprenant du n-(2-((3-(4-bromophenyl)-2- propenyl)amino)ethyl)-5-isoquinolinesulfonamide(h89)

Country Status (3)

Country Link
AR (1) AR057933A1 (fr)
FR (1) FR2893841B1 (fr)
WO (1) WO2007060182A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112903657B (zh) * 2021-01-28 2022-06-24 中山大学 一种三聚氰胺和甲醛的表面增强拉曼光谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2835252B1 (fr) * 2002-01-25 2005-08-05 Seppic Sa Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaicir la peau
US7256200B2 (en) * 2003-02-10 2007-08-14 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Method and composition for potentiating an oplate analgesic

Also Published As

Publication number Publication date
AR057933A1 (es) 2007-12-26
FR2893841A1 (fr) 2007-06-01
WO2007060182A1 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
FR14C0069I2 (fr) Composition pharmaceutique comprenant le lurasidone
CY2017038I1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν 4-(4-(3-(4-χλωρο-3-τριφθορομεθυλ-φαινυλ)-ουρειδο)-3-φθορο-φαινοξυ)-πυριδιν-2-καρβοξυλικο οξυ για thν θεραπευτικη αγωγη υπερπολλαπλασιαστικων διαταραχων
IL225167A (en) Annotations (para-methoxy) phenyl-sulfonamide, n- (isobutyl), n - [(r2) - hydroxy- (r3) - benzyl-profile]
EP1425019A4 (fr) Composition pharmaceutique
DK1799633T3 (da) Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
DK1651621T3 (da) 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL186308A (en) A pharmaceutical composition containing metformin hydrochloride and pioglitazone hydrochloride
DK1484970T3 (da) Benzamider og sammensætninger omfattende benzamider til anvendelse som fungicider
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
EP1987825A4 (fr) Composition pharmaceutique comprenant du phosphate d'oseltamivir
DK1587478T3 (da) Farmaceutisk sammensætning
EP1970076A4 (fr) Composition pharmaceutique pour application ungueale
EP1747004A4 (fr) Compositions pharmaceutiques pour insuffisances metaboliques
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
PL1771069T3 (pl) Pochodne N-(2-(hydroksymetylo)fenylo)-1H-pirazolo-4-karboksamidu i związki pokrewne jako mikrobójcze substancje czynne do zastosowania w ochronie roślin i materiałów
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
DK1643976T3 (da) Farmaceutisk formulering omfattende levothyroxinnatrium
JP2008510815A5 (ja) プラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）調節剤としてのオキサゾロ−ナフチル酸
ITPN20050014A1 (it) "piedino livellatore perfezionato"
EP1819323A4 (fr) Composition pharmaceutique renfermant un agent d'anti-nucleation
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf

Legal Events

Date Code Title Description
TP Transmission of property
RN Application for restoration

Effective date: 20130903

FC Decision of inpi director general to approve request for restoration

Effective date: 20140211

ST Notification of lapse

Effective date: 20140402

FC Decision of inpi director general to approve request for restoration

Effective date: 20140415

TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20140530

Owner name: LES LABORATOIRES D'ANJOU, FR

Effective date: 20140530

PLFP Fee payment

Year of fee payment: 11

CA Change of address

Effective date: 20160831

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20